Relieves pain during labor. ANDA 78400, held by Hikma Farmaceutica. Butorphanol Tartrate.
As of Nov 16, 2026, ANDA 78400 (Butorphanol Tartrate), held by Hikma Farmaceutica, was first approved by FDA on May 1, 2009, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Butorphanol Tartrate Injection is indicated: as a preoperative or pre-anesthetic medication as a supplement to balanced anesthesia for the relief of pain during labor, and for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses, reserve Butorphanol Tartrate Injection for use in patients for whom alternative treatment options [e.g.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 1, 2009 | Original application | Approved | None posted |
| Butorphanol Tartrate1MG/ML · injectable;injection | Butorphanol Tartrate | Rx |
| Butorphanol Tartrate2MG/ML · injectable;injection | Butorphanol Tartrate | Rx |
| Dec 22, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 16, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 16, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 15, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 1, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters